Basel, Switzerland, June 18, 2020 – Lonza has expanded its cell culture media portfolio with the addition of the GSv9™ Media and Feeds, providing a fully integrated solution specifically designed to optimize recombinant protein production using Lonza’s GS Gene Expression System®. The new chemically defined, animal-component free media and feeds are easy to implement, highly robust and enable greater batch-to-batch consistency. As a result, biopharmaceutical manufacturers can more easily develop streamlined and scalable bioproduction processes. The benefits enabled by the GSv9™ Media and Feeds will be demonstrated at a free 60-minute webinar on July 1, as well as through presentations at the Biologics Series: Virtual (27–28 August) and PEGS Virtual Interactive Global Summit (31 August–4 September). Recombinant proteins derived from mammalian cell lines are a key source of biopharmaceuticals designed to treat many complex human diseases. However, in such a highly competitive market, biopharmaceutical manufacturers must ensure that they maximize protein yield and consistency whilst also expediting production times. One way to achieve this is by using specially developed, simple-to-use media and feeds that improve cellular productivity, streamline processing and eliminate sources of product variability. With a focus on ease of implementation, Lonza is introducing the new GSv9™ Media and Feeds that deliver high performance with a simple and easy to use protocol. Furthermore, the solution has been developed using response surface optimization and multivariate propagation of error analysis to increase the intrinsic robustness of the production process. Additionally, the overall culturing time is designed for high facility throughput. Webinar: Meet the Experts: Introducing the GSv9™ Media and Feeds for Lonza’s GS System® Virtual symposium presentation: The Development of GSv9™ Media and Feeds: A High Performing and Easy to Use Optimized Media Platform for GS Xceed® Cell Line Virtual poster presentation: Development of a Simple Robust High Performance Platform Production Process for GS Xceed® Cell Line During the webinar, as well as at the Biologics Series: Virtual and PEGS Virtual Interactive Global Summit, Lonza experts will demonstrate how, through several complex analytical approaches, Lonza’s new solution has been designed to: · Increase process robustness for improved product consistency · Maximize cell concentration and protein yields · Reduce operational complexity for greater ease of use · Decrease batch duration for increased turnaround Key Dates to Note: Webinar · Wednesday, 01 July 2020 8 AM PDT (Los Angeles) · 11 AM EDT (New York) · 4 PM BST (London) · 5 PM CEST (Berlin) · Presenters: Colin Jaques, Ph.D. Technical Director, Lonza Biologics and Faraz Harsini, Ph.D., Protein Expression and Process Development Scientist, XBiotech USA Inc. By registering interest in the webinar, participants will also receive a link once it is available to watch “on demand” via the Lonza website. Biologics Series: Virtual Virtual symposium presentation including Q&A session · 27 August 2020, 11 AM · Presenters: Colin Jaques and Faraz Harsini Virtual poster presentation · 27–28 August 2020 (throughout event duration) PEGS Virtual Interactive Global Summit Virtual poster presentation · 31 August–4 September 2020 (throughout event duration) · Presenter: Colin Jaques More information about the GSv9™ Media and Feeds can be found at www.lonza.com/gsv9. For information about the webinar, please visit https://www.workcast.com/register?cpak=6538606379643961&referrer=pr. Further information about Lonza’s upcoming and on-demand webinars is available here: www.lonza.com/webinars. About Lonza At Lonza, we combine technological innovation with world class manufacturing and process excellence. Together, these enable our customers to deliver their discoveries in the healthcare, preservation, and protection sectors. We are a preferred global partner to the pharmaceutical, biotech and specialty ingredients markets. We work to prevent illness and promote a healthier world by enabling our customers to deliver innovative medicines that help treat or even cure a wide range of diseases. We also offer a broad range of microbial control solutions, which help to create and maintain a healthy environment. Founded in 1897 in the Swiss Alps, Lonza today operates in 120 sites and offices in more than 35 countries. With approximately 15,500 full-time employees, we are built from high-performing teams and of individual employees who make a meaningful difference to our own business, as well as the communities in which we operate. The company generated sales of CHF 5.9 billion in 2019 with a CORE EBITDA of CHF 1.6 billion. Find out more at www.lonza.com and follow us on Twitter @LonzaGroup or Facebook @LonzaGroupAG. Lonza Contact Details Dr. Kristin Koehler Investor Relations Lonza Group Ltd Tel +41 61 316 8782 kristin.koehler@lonza.com Dr. Sanna Fowler Head of External Communications Lonza Group Ltd Tel +41 61 316 8929 sanna.fowler@lonza.com Additional Information and Disclaimer Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual. Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release. | 
